11,896 results match your criteria Ovarian Cancer* Obstetrics and Gynecology


Inhibition of sphingosine kinase 2 down-regulates ERK/c-Myc pathway and reduces cell proliferation in human epithelial ovarian cancer.

Ann Transl Med 2021 Apr;9(8):645

Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: Epithelial ovarian cancer (EOC) is the leading cause of death from female cancers. In our previous study, sphingosine kinase 2 (SphK2) inhibitor was shown to display anti-EOC activities. The purpose of this study was to evaluate further the expression characteristics and clinical significance of SphK2 in EOC and to explore the roles and underlying mechanisms of SphK2 in EOC cell survival. Read More

View Article and Full-Text PDF

Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.

Eur J Obstet Gynecol Reprod Biol 2021 Apr 18;262:13-20. Epub 2021 Apr 18.

Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University, Taoyuan, Taiwan. Electronic address:

Objective: The objective of this study is to evaluate the safety and efficacy of adding bevacizumab to dose-dense adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Study Design: This phase II clinical trial using Simon's minimax two-stage design was conducted. At the first stage, 13 subjects were enrolled, and the trial would proceed to second stage if ≤3 subjects discontinued treatment for study-defined significant adverse events (AEs). Read More

View Article and Full-Text PDF

Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Authors:
S I Kim J-W Kim

ESMO Open 2021 May 10;6(3):100149. Epub 2021 May 10.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:

Ovarian cancer is one of the deadliest gynaecological malignancies and tends to be diagnosed at an advanced stage. Similar to many malignancies, surgery plays a critical role in many aspects of ovarian cancer management. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the induction of hyperthermia and delivery of intraperitoneal chemotherapy directly into the peritoneal cavity. Read More

View Article and Full-Text PDF

Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.

Cancer 2021 May 13. Epub 2021 May 13.

Division of Gynecologic Oncology, Princess Margaret Cancer Centre/University Health Network/Sinai Health Systems, Toronto, Ontario, Canada.

Background: Despite recommendations for reflex immunohistochemistry (IHC) for mismatch repair (MMR) proteins to identify Lynch syndrome (LS), the uptake of genetic assessment by those who meet referral criteria is low. The authors implemented a comprehensive genetic navigation program to increase the uptake of genetic testing for LS in patients with endometrial cancer (EC) or nonserous/nonmucinous ovarian cancer (OC).

Methods: Participants with newly diagnosed EC or OC were prospectively recruited from 3 cancer centers in Ontario, Canada. Read More

View Article and Full-Text PDF

RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.

Cell Biol Toxicol 2021 May 11. Epub 2021 May 11.

Department of Gastroenterology, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, No. 66, Renmin South Road, Yancheng, 224001, Jiangsu, China.

Objective: Cancer stem cells (CSCs) are the main driving force of tumorigenesis, metastasis, recurrence, and drug resistance in epithelial ovarian cancer (EOC). The current study aimed to explore the regulatory effects of ring finger protein 144A (RNF144A), an E3 ubiquitin ligase, in the maintenance of CSC properties and tumor development in EOC.

Methods: The expressions of RNF144A in EOC tissue samples and cells were examined. Read More

View Article and Full-Text PDF

Ultrasensitive Vibrational Imaging of Retinoids by Visible Preresonance Stimulated Raman Scattering Microscopy.

Adv Sci (Weinh) 2021 05 8;8(9):2003136. Epub 2021 Feb 8.

Department of Biomedical Engineering Boston University Boston MA 02215 USA.

High-sensitivity chemical imaging offers a window to decipher the molecular orchestra inside a living system. Based on vibrational fingerprint signatures, coherent Raman scattering microscopy provides a label-free approach to map biomolecules and drug molecules inside a cell. Yet, by near-infrared (NIR) pulse excitation, the sensitivity is limited to millimolar concentration for endogenous biomolecules. Read More

View Article and Full-Text PDF

The natural compound n-butylidenephthalide kills high-grade serous ovarian cancer stem cells by activating intrinsic apoptosis signaling pathways.

J Cancer 2021 30;12(11):3126-3135. Epub 2021 Mar 30.

Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, and Tzu Chi University, Hualien, Taiwan.

High-grade serous ovarian cancer (HGSOC) constitutes 80% of ovarian cancer. Cancer stem cells (CSCs) are responsible for most of the tumor metastasis and chemoresistance. n-Butylidenephthalide (BP) is a potential anti-tumor agent for treating a variety of cancers. Read More

View Article and Full-Text PDF

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Genet Med 2021 May 11. Epub 2021 May 11.

Department of Medicine, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Purpose: PALB2 germline pathogenic variants are associated with increased breast cancer risk and smaller increased risk of pancreatic and likely ovarian cancer. Resources for health-care professionals managing PALB2 heterozygotes are currently limited.

Methods: A workgroup of experts sought to outline management of PALB2 heterozygotes based on current evidence. Read More

View Article and Full-Text PDF

LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.

Apoptosis 2021 May 11. Epub 2021 May 11.

Department of Obstetrics and Gynecology, The Third Hospital of Jilin University, 126th Xiantai Street, Changchun, 130021, Jilin, China.

Long non-coding RNAs (lncRNAs) have been reported to participate in regulating gene expression and are related to tumor progression. FGD5 antisense RNA 1 (FGD5-AS1) facilitates the progression of various tumors. However, the expression and function of FGD5-AS1 in ovarian cancer (OC) and its mechanism of action are not yet clear. Read More

View Article and Full-Text PDF

Application of artificial intelligence in gynecologic malignancies: A review.

J Obstet Gynaecol Res 2021 May 10. Epub 2021 May 10.

Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

With the development of machine learning and deep learning models, artificial intelligence is now being applied to the field of medicine. In oncology, the use of artificial intelligence for the diagnostic evaluation of medical images such as radiographic images, omics analysis using genome data, and clinical information has been increasing in recent years. There have been increasing numbers of reports on the use of artificial intelligence in the field of gynecologic malignancies, and we introduce and review these studies. Read More

View Article and Full-Text PDF

Integration and interplay of machine learning and bioinformatics approach to identify genetic interaction related to ovarian cancer chemoresistance.

Brief Bioinform 2021 May 10. Epub 2021 May 10.

School of Public health and Community Medicine, University of New South Wales, 2052, Sydney, Australia.

Although chemotherapy is the first-line treatment for ovarian cancer (OCa) patients, chemoresistance (CR) decreases their progression-free survival. This paper investigates the genetic interaction (GI) related to OCa-CR. To decrease the complexity of establishing gene networks, individual signature genes related to OCa-CR are identified using a gradient boosting decision tree algorithm. Read More

View Article and Full-Text PDF

Activation of COL11A1 by PRRX1 promotes tumor progression and radioresistance in ovarian cancer.

Int J Radiat Biol 2021 May 10:1-29. Epub 2021 May 10.

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Nanjing Medical University, No. 262, Zhongshanbei Road, Gulou District, Nanjing 210003, Jiangsu, China.

Purpose: Although radiotherapy is a common treatment option for all kinds of cancer patients, including ovarian cancer, a major obstacle limiting its application is the development of resistance. Therefore, it is urgently needed to clarify the mechanism of radio sensitivity modulation.

Materials And Methods: We obtained open datasets and analyzed the expression of collagen type XI alpha 1 (COL11A1) in ovarian cancer patients with different stages. Read More

View Article and Full-Text PDF

Systematic review and meta-analysis on the impact of the levonorgestrel-releasing intrauterine system in reducing risk of ovarian cancer.

Int J Gynaecol Obstet 2021 May 9. Epub 2021 May 9.

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Background: Ovarian carcinoma (OC) is one of the most widespread tumors in the world and is characterized by low survival rates.

Objective: To determine whether the levonorgestrel-releasing intrauterine system (LNG-IUS) can prevent OC.

Search Strategy: The literature until December 2020 were systematically reviewed according to the PRISMA Statement for Reporting Systematic Reviews (PROSPERO: CRD42019137957). Read More

View Article and Full-Text PDF

Clinical Phenotypes of Tumors Invading the Rectosigmoid Colon Affecting the Extent of Debulking Surgery and Survival in Advanced Ovarian Cancer.

Front Oncol 2021 22;11:673631. Epub 2021 Apr 22.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.

We classified clinical phenotypes based on tumor separability from the rectosigmoid colon and then evaluated the effect of these clinical phenotypes on surgical outcomes and prognosis of advanced ovarian cancer. We collected data of patients with stage IIIB-IVB disease who either underwent visceral segmental serosectomy (VSS) or low anterior resection (LAR) during maximal debulking surgery. All patients were divided into the following, according to the resection types of tumors involving the rectosigmoid colon: the focal (tumor-involved length <18 cm) and separable (FS) group that received VSS, the focal and inseparable (FI) that received LAR, or the diffuse (tumor-involved length ≥18 cm) group (D) that also received LAR. Read More

View Article and Full-Text PDF

C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.

Oncogene 2021 May 8. Epub 2021 May 8.

Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

PARP inhibitors (PARPi) are efficacious in treating high-grade serous ovarian cancer (HG-SOC) with homologous recombination (HR) deficiency. However, they exhibit suboptimal efficiency in HR-proficient cancers. Here, we found that the expression of CCAAT/enhancer-binding protein β (C/EBPβ), a transcription factor, was inversely correlated with PARPi sensitivity in vitro and in vivo, both in HR-proficient condition. Read More

View Article and Full-Text PDF

The Role of Bone Morphogenetic Protein 4 in Ovarian Function and Diseases.

Reprod Sci 2021 May 8. Epub 2021 May 8.

Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Bone morphogenetic proteins (BMPs) are the largest subfamily of the transforming growth factor-β (TGF-β) superfamily. BMP4 is a secreted protein that was originally identified due to its role in bone and cartilage development. Over the past decades, extensive literature has indicated that BMP4 and its receptors are widely expressed in the ovary. Read More

View Article and Full-Text PDF

Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.

Int J Cancer 2021 May 8. Epub 2021 May 8.

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Little is known about the influence of pre- and post-diagnosis physical activity on ovarian cancer survival. We investigated this association in two large cohorts, the Nurses' Health Study (NHS) and NHSII. Analyses included 1461 women with confirmed invasive, epithelial ovarian cancer and data on physical activity. Read More

View Article and Full-Text PDF

[ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics].

Nan Fang Yi Ke Da Xue Xue Bao 2021 Apr;41(4):555-561

Southern Medical University of Nanfang Hospital, Obstetrics and Gynecology Department, Guangzhou 510515, China.

Objective: To investigate the expression of ENTPD5 in epithelial ovarian cancer and explore its clinical implications.

Objective: The expression level of ENTPD5 in epithelial ovarian cancer was analyzed based on data from Oncomine and TCGA databases. The relationship between the expression level of ENTPD5 and clinical characteristics of the patients was analyzed using UALCAN database. Read More

View Article and Full-Text PDF

WNT4 balances development versus disease in gynecologic tissues and women's health.

Endocrinology 2021 May 8. Epub 2021 May 8.

Dept. of Pathology, University of Colorado Anschutz Medical Campus.

The WNT family of proteins are crucial in numerous developmental pathways and tissue homeostasis. WNT4, in particular, is uniquely implicated in development of the female phenotype in the fetus, and in the maintenance of Müllerian and reproductive tissues. WNT4 dysfunction or dysregulation can drive sex reversal syndromes, highlighting the key role of WNT4 in sex determination. Read More

View Article and Full-Text PDF

Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Advanced Colorectal or Ovarian Cancer.

Ann Surg Oncol 2021 May 6. Epub 2021 May 6.

Department of Surgery, University of Chicago, Chicago, IL, USA.

Background: Cytoreductive surgery (CRS) for ovarian cancer with peritoneal metastases (OPM) is an established treatment, yet access-related racial and socioeconomic disparities are well documented. CRS for colorectal cancer with peritoneal metastases (CRPM) is garnering more widespread acceptance, and it is unknown what disparities exist with regards to access.

Methods: This retrospective cross-sectional multicenter study analyzed medical records from the National Cancer Database from 2010 to 2015. Read More

View Article and Full-Text PDF

A Novel Clinical Nomogram for Predicting Cancer-Specific Survival in Adult Patients After Primary Surgery for Epithelial Ovarian Cancer: A Real-World Analysis Based on the Surveillance, Epidemiology, and End Results Database and External Validation in a Tertiary Center.

Front Oncol 2021 20;11:670644. Epub 2021 Apr 20.

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Background: The present study aimed to construct and validate a nomogram that can be used to predict cancer-specific survival (CSS) in patients with epithelial ovarian cancer (EOC).

Methods: A total of 7,129 adult patients with EOC were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Patients were randomly divided into the training and validation cohorts (7:3). Read More

View Article and Full-Text PDF

Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Ovarian Cancer.

Obstet Gynecol 2021 May 6. Epub 2021 May 6.

Department of Gynecologic Oncology and Reproductive Medicine, the Department of Health Services Research, Division of Cancer Prevention and Population Sciences, and the Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas; the Department of Obstetrics and Gynecology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts; the Department of Obstetrics and Gynecology, the University of Texas Medical Branch at Galveston, Galveston, Texas; and the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, and the Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York.

Objective: To evaluate the outcomes of the first pregnancy after fertility-sparing surgery in patients treated for early-stage ovarian cancer.

Methods: We performed a retrospective study of women aged 18-45 years with a history of stage IA or IC ovarian cancer reported to the California Cancer Registry for the years 2000-2012. These data were linked to the 2000-2012 California Office of Statewide Health Planning and Development birth and discharge data sets to ascertain oncologic characteristics and obstetric outcomes. Read More

View Article and Full-Text PDF

Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II.

Mol Med Rep 2021 Jul 6;24(1). Epub 2021 May 6.

Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning 110000, P.R. China.

The aim of the present study was to investigate the effects of human epididymis protein 4 (HE4) on drug resistance and its underlying mechanisms. The associations among proteins were detected by immunoprecipitation and immunofluorescence assays. Then, stably transfected cell lines CAOV3‑HE4‑L and CAOV3‑A2‑L expressing HE4 short hairpin (sh)RNAs and ANXA2 shRNAs, respectively, were constructed. Read More

View Article and Full-Text PDF

Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.

Cancer Med 2021 May 5. Epub 2021 May 5.

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Although the association between tumor-infiltrating CD3 T and CD8 T cells and superior survival in high-grade serous ovarian cancer (HGSOC) has been observed, the different spatial localization of tumor-infiltrating lymphocytes (TILs) possesses heterogeneous effects. We performed localized measurements in 260 HGSOC from 2 independent cohorts represented in tissue microarray format to determine the localized expression pattern and clinical significance of CD3 T, CD8 T, and CD45RO cells in HGSOC. Different density of spatial localization of CD3 T, CD8 T, and CD45RO cells exhibited heterogeneous association with OS. Read More

View Article and Full-Text PDF

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer.

Cancer Cell Int 2021 May 5;21(1):249. Epub 2021 May 5.

Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.

Background: Ovarian cancer has greatly endangered and deteriorated female health conditions worldwide. Refinement of predictive biomarkers could enable patient stratification and help optimize disease management.

Methods: RAD51 expression profile, target-disease associations, and fitness scores of RAD51 were analyzed in ovarian cancer using bioinformatic analysis. Read More

View Article and Full-Text PDF

Conditional disease-free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15-year retrospective cohort study.

Cancer Rep (Hoboken) 2021 May 5:e1416. Epub 2021 May 5.

Oral and Dental Disease Research Center, Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: The most common type of ovarian cancer (OC) is epithelial ovarian cancer (EOC) which is the most lethal gynecologic malignancy in adult women.

Aim: This study aimed to determine the conditional disease-free survival (CDFS) rates and their associated determinants in patients with EOC.

Methods And Results: The clinical and demographic data of 335 patients with confirmed EOC at Motahari Clinic (Shiraz, Iran) were retrospectively reviewed and analyzed. Read More

View Article and Full-Text PDF

Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.

Biomater Sci 2021 May 5. Epub 2021 May 5.

Department of Pharmacy, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan 528300, P. R. China. and A School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, P. R. China.

As the most common cause of gynecological cancer-related deaths worldwide, ovarian cancer requires novel therapy strategies. Pt(ii)-Based antitumor drugs (e.g. Read More

View Article and Full-Text PDF

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.

BMC Cancer 2021 May 4;21(1):499. Epub 2021 May 4.

ACT Genomics, Co. Ltd., 3F., No.345, Xinhu 2nd Rd., Neihu Dist, Taipei City, 114, Taiwan.

Background: Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alteration patterns of individual patients.

Methods: We sequenced 410 genes to analyze mutations and CNV of 82 ovarian carcinomas, including high-grade serous (n = 37), endometrioid (n = 22) and clear cell (n = 23) histologies. Read More

View Article and Full-Text PDF

The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer.

Expert Rev Mol Diagn 2021 May 14:1-11. Epub 2021 May 14.

Department of Obstetrics and Gynecology, Technische Universität München, Munich, Germany.

Ovarian cancer is one of the deadliest malignancies among women worldwide. The lack of early diagnostic markers fuels an unfavorable prognosis as most patients are at an advanced stage when the disease is diagnosed for the first time. The role of the kallikrein-related peptidase (KLK) family in ovarian cancer progression and prognosis has been thoroughly investigated in various studies. Read More

View Article and Full-Text PDF